Trials / Unknown
UnknownNCT04353193
Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial.
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Juan A. Arnaiz · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Clinical trial to compare the effects of terlipressin and octreotide in the reduction of portal hypertension measured as hepatic venous pressure gradient (HVPG) in patients with liver cirrhosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Terlipressin | Terlipressin 1mg IV bolus |
| DRUG | Terlipressin | Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours |
| DRUG | Octreotide | Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2022-02-01
- Completion
- 2022-05-01
- First posted
- 2020-04-20
- Last updated
- 2020-04-20
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT04353193. Inclusion in this directory is not an endorsement.